Original articleUncovering burden disparity: A comparative analysis of the impact of moderate-to-severe psoriasis and hidradenitis suppurativa
Section snippets
Study design
Five international clinical trials of adalimumab for HS and plaque psoriasis that included at least 1 US study site were selected. A comparative analysis of HRQoL measures among populations pooled from selected clinical trials was conducted using baseline values. This study was exempt from review by an institutional review board (IRB).
Description of included trials
For HS, 3 trials were included: PIONEER I (a phase III, multicenter study of the safety and efficacy of adalimumab in subjects with moderate-to-severe HS),
Study characteristics
Baseline demographic and disease characteristics were compared between respective HS and psoriasis studies (Table II). Patient demographics and duration and severity of disease were similar between individual psoriasis study populations. The severity distribution of HS populations differed; the PIONEER trials included a larger proportion of Hurley stage III patients with HS compared with the proportion of such patients in NCT00918255 because of different inclusion criteria (ie, patients with
Discussion
This study suggests that patients with moderate-to-severe HS experience greater pain, increased work impairment, and reduced HRQoL than do patients with moderate-to-severe plaque psoriasis. The analysis corroborates previous findings that HS imposes a higher HRQoL burden than other dermatologic conditions, including psoriasis.2, 32
Although the literature demonstrates that both HS and psoriasis are associated with chronic and debilitating pain, the magnitude of pain has not been previously
Conclusion
These results illustrate the greater burden on the HRQoL of patients with HS than on the HRQoL of patients with psoriasis according to the 5 HRQoL measures (VAS-pain, DLQI, EQ-5D VAS, SF-36 PCS, and SF-36 MCS). The greater impact on HRQoL in patients with HS may contribute to the higher cost of managing HS compared with that of managing psoriasis.28, 35 Untreated patients with HS present greater HRQoL impairments than do patients with psoriasis; thus, the relative change in HRQoL following
References (67)
- et al.
Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis?
J Am Acad Dermatol
(2000) - et al.
Incidence of hidradenitis suppurativa and associated factors: a population-based study of Olmsted County, Minnesota
J Invest Dermatol
(2013) - et al.
The prevalence of metabolic syndrome in patients with hidradenitis suppurativa
J Am Acad Dermatol
(2014) - et al.
Hidradenitis suppurativa (Verneuil’s disease)
Journal of the Saudi Society of Dermatology and Dermatologic Surgery
(2013) - et al.
Hidradenitis suppurativa: a comprehensive review
J Am Acad Dermatol
(2009) - et al.
Coronary heart disease and stroke risk in patients with psoriasis: retrospective analysis
Am J Med
(2010) - et al.
Prevalence of psoriasis among adults in the U.S.: 2003-2006 and 2009-2010 National Health and Nutrition Examination Surveys
Am J Prev Med
(2014) - et al.
Prevalence of cardiovascular risk factors in patients with psoriasis
J Am Acad Dermatol
(2006) - et al.
Evaluating the economic burden of psoriasis in the United States
J Am Acad Dermatol
(2015) - et al.
The burden of psoriasis: a study concerning health-related quality of life among Norwegian adult patients with psoriasis compared with general population norms
J Am Acad Dermatol
(2000)
Quality of life in patients with psoriasis: a systematic literature review
J Investig Dermatol Symp Proc
Determinants of quality of life in patients with psoriasis: a study from the US population
J Am Acad Dermatol
Quality of life impairment in hidradenitis suppurativa: a study of 61 cases
J Am Acad Dermatol
Quantifying the harmful effect of psoriasis on health-related quality of life
J Am Acad Dermatol
Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics
J Am Acad Dermatol
Hidradenitis suppurativa: epidemiology and scope of the problem
J Am Acad Dermatol
Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial
J Am Acad Dermatol
Ethnicity and hidradenitis suppurativa
J Invest Dermatol
Morbidity in patients with hidradenitis suppurativa
Br J Dermatol
Connections between psoriasis and Crohn’s disease
J Am Acad Dermatol
The differential diagnosis and comorbidity of hidradenitis suppurativa and perianal Crohn’s disease
Int J Colorectal Dis
Psoriasis: depression, anxiety, smoking, and drinking habits
Dermatol Ther
Psychiatric comorbidities in 3207 patients with hidradenitis suppurativa
J Eur Acad Dermatol Venereol
Impact of obesity and smoking on psoriasis presentation and management
Arch Dermatol
Prevalence of the metabolic syndrome in psoriasis: results from the National Health and Nutrition Examination Survey, 2003-2006
Arch Dermatol
Hidradenitis suppurativa complicated by squamous cell carcinoma
Am Surg
Risk of cancer in psoriasis: a systematic review and meta-analysis of epidemiological studies
J Eur Acad Dermatol Venereol
The natural history of hidradenitis suppurativa
J Eur Acad Dermatol Venereol
Psoriasis: epidemiology, clinical features, and quality of life
Ann Rheum Dis
Risk of myocardial infarction in patients with psoriasis
JAMA
Psoriasis: evolving treatment for a complex disease
Cleve Clin J Med
Risk of major adverse cardiovascular events and all-cause mortality in patients with hidradenitis suppurativa
JAMA Dermatol
Management of hidradenitis suppurativa in patients with metabolic comorbidities
Ann Dermatol
Cited by (36)
Understanding the systemic burden of disease in hidradenitis suppurativa from plasma lipidomic analysis
2022, Journal of Dermatological ScienceCitation Excerpt :The prevalence has been reported to range from 0.078% to 4% [2–4]. There is a positive association between HS and smoking, obesity and the metabolic syndrome [5–9] which is stronger than that of psoriasis, another inflammatory skin condition associated with metabolic comorbidities [10]. Although HS is associated with inflammation, obesity and the metabolic syndrome, the nature and reason for this and the role of lipids in HS pathogenesis remains poorly understood.
Hidradenitis Suppurativa Epidemiology
2022, A Comprehensive Guide to Hidradenitis SuppurativaQuality of Life
2022, A Comprehensive Guide to Hidradenitis SuppurativaPain management in hidradenitis suppurativa and a proposed treatment algorithm
2021, Journal of the American Academy of DermatologyA systematic review of 454 randomized controlled trials using the Dermatology Life Quality Index: experience in 69 diseases and 43 countries
2024, British Journal of Dermatology
Design, study conduct, and financial support for the study were provided by AbbVie Inc, which participated in interpretation of the data and review and approval of the manuscript. All authors contributed to the development of the publication and maintained control over the final content.
Disclosure: Dr Hamzavi has served or currently serves as an investigator in clinical trial activities for AbbVie Inc, Adelphi Values, and The Microdermis Corporation, with research grants paid to his institution, and he is also the current president of the Hidradenitis Suppurativa Foundation in a nonfunded position. Drs Arikian, Zivkovic, and Lee and Ms Yi have current consulting agreements with AbbVie Inc. Dr Okun is a consultant to United BioSource Corporation (UBC), serves on the speaker's bureau for AbbVie Inc, is a former AbbVie employee, and may have owned AbbVie Inc, stock or stock options. Drs Ganguli and Yihua Gu are employees of AbbVie Inc, and may own AbbVie Inc, stock or stock options. Dr Sundaram is a former employee of AbbVie Inc, and may have owned AbbVie Inc stock or stock options. Ms Parks-Miller serves or has served on an advisory board for AbbVie Inc, has a current consulting agreement with AbbVie Inc, receives funding as the national coordinator of advocacy and support for the Hidradenitis Suppurativa Foundation, and is the founding director of Hope for Hidradenitis Suppurativa. Dr Nicholson is a nonfunded committee member for the Hidradenitis Suppurativa Foundation.